Your browser doesn't support javascript.
loading
: 20 | 50 | 100
1 - 8 de 8
1.
Int Clin Psychopharmacol ; 34(4): 206-210, 2019 07.
Article En | MEDLINE | ID: mdl-30998596

Hyponatremia is occasionally unmasked in psychiatric patients during hospitalization after routine blood and urinary tests, and correlates in most cases with an inappropriate secretion of antidiuretic hormone, mainly due to iatrogenic factors. Only a few studies have regarded the combination of psychotropic drugs as triggers of chronic, asymptomatic hyponatremia in bipolar patients, who require to be hospitalized because of the exacerbation of their mental illness. We presented three clinical cases of patients affected by a long-term psychiatric disorder and under polypharmacotherapy for several months. After excluding other potential factors, we hypothesized that pharmacological treatment with a mood stabilizer (oxcarbazepine) associated with a benzodiazepine (delorazepam), a second-generation antipsychotic (olanzapine) or an antidepressant (fluvoxamine), triggered severe hyponatremia ([Na+] ≤125 mEq/L), serum hypo-osmolarity, and elevated inappropriate urine osmolarity added to more diluted sodium concentration. When we discontinued the treatment, clinical conditions of our patients improved, despite the previous administration of hypertonic saline jointly with water restriction. Psychiatrists should consider that bipolar patients on long-term polypharmacotherapy may present a higher risk of severe hyponatremia not clinically detectable. Consequently, routine laboratory tests should be periodically repeated as they represent the only available tool to unmask such electrolyte imbalances.


Benzodiazepines/adverse effects , Bipolar Disorder/drug therapy , Hyponatremia/chemically induced , Hyponatremia/etiology , Nordazepam/analogs & derivatives , Olanzapine/adverse effects , Oxcarbazepine/adverse effects , Adult , Anti-Anxiety Agents/adverse effects , Antipsychotic Agents/adverse effects , Female , Humans , Male , Middle Aged , Nordazepam/adverse effects , Psychotropic Drugs/adverse effects
2.
Ann Pharm Fr ; 75(3): 163-171, 2017 May.
Article En | MEDLINE | ID: mdl-28242100

OBJECTIVES: Toxicodynetics aims at defining the time-course of major clinical events in drug overdose. We report the toxicodynetics in mono-intoxications with oxazepam and nordiazepam. METHODS: Cases of oxazepam or nordiazepam overdoses collected at the Paris poison control centre from 1999 to 2014 on the basis of self-report. A particular attention was paid to eliminate the concomitant alcohol or psychotropic co-ingestions. The toxicodynetic parameters were assessed as previously described. Results are expressed using 10-90 percentiles. In adults, the dose was normalized (TI, toxic Index) by dividing the supposed ingested dose by the maximal recommended dose. RESULTS: Two hundred and fifty-one and 74 cases of oxazepam and nordiazepam poisonings were included, respectively. The Emax for oxazepam and nordiazepam were sleepiness or obtundation in 106 and 36 cases, respectively. Coma was used to qualify only one oxazepam overdose. The median delay in onset of the Emax was 1.5h (0.33-15) in nordiazepam and 4h (0.5-15) in oxazepam overdose. In both overdoses, the onset of Emax occurred on an "on-off" mode. In adults, the greatest TIs in nordiazepam and oxazepam overdoses were 45 and 26.7, respectively. The TI in the oxazepam-induced coma was 26.7, the largest dose. CONCLUSION: Data collected in PCC allow determining a number of toxicodynetic parameters. Toxicodynetics showed that nordiazepam is not a cause of coma even in large overdose while oxazepam causes coma only at a very high dose. Deep coma in nordiazepam overdose whatever the dose and deep coma in overdose with oxazepam involving TI less than 20 result from unrecognized drug-drug interaction.


Drug Overdose/metabolism , GABA Modulators/adverse effects , GABA Modulators/pharmacokinetics , Nordazepam/adverse effects , Nordazepam/pharmacokinetics , Oxazepam/adverse effects , Oxazepam/pharmacokinetics , Toxicokinetics , Adolescent , Adult , Aging/metabolism , Central Nervous System Depressants/adverse effects , Child , Child, Preschool , Ethanol/adverse effects , Female , Humans , Male , Middle Aged , Retrospective Studies , Young Adult
3.
Anaesthesiol Reanim ; 20(6): 144-8, 1995.
Article De | MEDLINE | ID: mdl-8652038

Clorazepate dipotassium (Tranxilium) is one of the benzodiazepines which is widely used for oral premedication. After oral administration it is decarboxylated to its active metabolite nordiazepam (desmethyldiazepam). Nordiazepam is also commercially available in the form of drops (Tranxilium N). The aim of the present study was to compare the effect of these drugs on preoperative anxiety. One hundred and eight patients scheduled for orthopaedic surgery (ASA I-II) were studied. Medication was administered at 10 p.m. the evening before surgery (E) and at 7 a.m. on the morning of surgery (M). There were four groups: 1) E no medication; M clorazepate dipotassium; 2) E no medication; M nordiazepam; 3) E clorazepate dipotassium; M clorazepate dipotassium, 4) E clorazepate dipotassium; M nordiazepam. Dosages were: clorazepate dipotassium: body weight < 55 kg: 10 mg; body weight > 55 kg: 20 mg; nordiazepam: 1 gtt/kg; 5 mg = 24 gtt). Anxiety was measured by using the self-evaluating Erlangen anxiety scales, which measure both background and situational anxiety. Background anxiety (EAS-H) was evaluated during the evening before surgery; situational anxiety (EAS-S) was evaluated at the same time and also on the day of surgery before premedication and immediately before surgery. Pulse rate was measured each time the test was administered. There were no differences between the groups in sex, age, weight or the intervals between premedication and anaesthesia induction (p > 0.05). There were no statistically significant differences between the groups with respect to background anxiety. Situational anxiety did not significantly increase or decrease at any of the testing times, nor were there any differences between the groups (p > 0.05). Heart rate did not vary between the groups or with time (p > 0.05). In this group of patients undergoing elective orthopaedic procedures, clorazepate prevented a rise in anxiety in the immediate preoperative period. Since clorazepate is rapidly metabolized to nordiazepam when administered orally it might be predicted that the two drugs have similar properties. This hypothesis is confirmed by the results of the present study. We conclude that orally administered clorazepate dipotassium and nordiazepam have a similar effect on preoperative anxiety.


Anti-Anxiety Agents/administration & dosage , Anxiety/drug therapy , Clorazepate Dipotassium/administration & dosage , Nordazepam/administration & dosage , Preanesthetic Medication , Surgical Procedures, Operative/psychology , Administration, Oral , Adult , Aged , Anti-Anxiety Agents/adverse effects , Clorazepate Dipotassium/adverse effects , Dose-Response Relationship, Drug , Drug Administration Schedule , Female , Humans , Male , Middle Aged , Nordazepam/adverse effects , Orthopedics , Personality Inventory , Prospective Studies
4.
Minerva Anestesiol ; 60(4): 181-4, 1994 Apr.
Article It | MEDLINE | ID: mdl-7916445

Forty patients over 65 undergoing subarachnoid anesthesia with bupivacaine 0.50% (5 mg) and fentanyl (0.1 mg) were subdivided into two equal groups: one was premedicated with atropine and chlordesmethyldiazepam (0.03 mg/kg-1) and the other with atropine and diazepam (0.015 mg/Kg-1). A statistically significant difference was found in the group treated with diazepam which required an increase for anesthetic drugs during surgery. The authors suggest a probable synergic or an enhanced effect between intramuscular chlordesmethyldiazepam and opiates in spinal anesthesia.


Anesthesia, Spinal , Anti-Anxiety Agents , Benzodiazepines , Diazepam , Nordazepam/analogs & derivatives , Preanesthetic Medication , Aged , Anti-Anxiety Agents/adverse effects , Diazepam/adverse effects , Female , Humans , Male , Nordazepam/adverse effects
5.
Int J Clin Pharmacol Res ; 6(4): 309-14, 1986.
Article En | MEDLINE | ID: mdl-2875955

The kinetics of delorazepam (chlordesmethyldiazepam; CDDZ), and its major metabolite, lorazepam (LRZ) during multiple-dose therapy have been evaluated in two groups of patients with primary or secondary anxiety. The 12 patients in group 1 were 46.8 +/- less than 13.2 years while the eight in group 2 were significantly older (69.7 +/- 7.8 years). All patients were given 0.5 mg twice daily of CDDZ for 30 days. Concentrations of CDDZ and LRZ in multiple blood samples collected during the study were determined by electron-capture gas-liquid chromatography. The degree of anxiety was evaluated from the Hamilton rating scale for anxiety (HRSA). CDDZ and LRZ accumulated in plasma but the rate of accumulation of CDDZ was slower than expected from studies in young volunteers and the half-life values were significantly related to age. Steady-state levels of glucuronated LRZ were also lower in elderly patients. Data indicate that CDDZ is more slowly eliminated and less metabolized as age increases. While pre-treatment scores of HRSA were similar in the two groups, older patients improved significantly less than those of group 1 and had also an higher incidence of side-effects. CDDZ levels positively correlated with improvement in group 1 but not in group 2.


Aging/blood , Anti-Anxiety Agents/blood , Anxiety Disorders/blood , Benzodiazepines , Diazepam/analogs & derivatives , Nordazepam/analogs & derivatives , Adult , Aged , Anti-Anxiety Agents/administration & dosage , Anti-Anxiety Agents/adverse effects , Anxiety Disorders/drug therapy , Female , Humans , Kinetics , Male , Middle Aged , Nordazepam/administration & dosage , Nordazepam/adverse effects , Nordazepam/blood
6.
J Pharmacol Exp Ther ; 235(2): 368-76, 1985 Nov.
Article En | MEDLINE | ID: mdl-3932642

Dogs, surgically implanted with a chronic gastric fistula, were chronically dosed with N-desmethyldiazepam (32 mg/kg/day) in four divided doses to attain N-desmethyldiazepam plasma levels comparable to those observed in dogs dependent on diazepam (60 mg/kg/day). The time course of N-desmethyldiazepam abstinence was studied, beginning not less than 2 weeks after stabilization levels had been achieved. The abstinence syndrome observed after abrupt discontinuation of N-desmethyldiazepam was similar to the diazepam abstinence syndrome but differed in several important aspects. In diazepam-dependent dogs, there was a short burst of tremor very early in withdrawal (approximately 1-2 hr after the last dose of diazepam) that was not seen in N-desmethyldiazepam-dependent dogs. Signs of abstinence such as tremor, hot foot walking and twitches and jerks were more frequently observed in N-desmethyldiazepam-dependent dogs than in diazepam-dependent dogs as were decreases in food and water intake and in body weight. The overall intensity of abstinence, as measured by the Diazepam Withdrawal Abstinence Scale, was greater in N-desmethyldiazepam-dependent dogs than in dogs dependent on either lorazepam or diazepam. Plasma levels of N-desmethyldiazepam and oxazepam were nearly equal in dogs dependent on diazepam or on N-desmethyldiazepam and were 4 to 10 times greater than the plasma levels of diazepam or lorazepam in diazepam- or lorazepam-dependent dogs, respectively. Furthermore, the plasma levels of N-desmethyldiazepam and oxazepam declined much more slowly than the levels of diazepam and lorazepam. These results suggest that physical dependence on diazepam is caused by the accumulation and actions of N-desmethyldiazepam.(ABSTRACT TRUNCATED AT 250 WORDS)


Diazepam/analogs & derivatives , Nordazepam/adverse effects , Substance Withdrawal Syndrome/physiopathology , Analysis of Variance , Animals , Body Weight/drug effects , Diazepam/adverse effects , Diazepam/blood , Dogs , Drinking/drug effects , Energy Intake/drug effects , Female , Lorazepam/adverse effects , Lorazepam/blood , Muscle Spasticity/chemically induced , Nordazepam/blood , Oxazepam/adverse effects , Oxazepam/blood , Paresthesia/chemically induced , Temazepam/adverse effects , Temazepam/blood , Time Factors
7.
Am J Psychiatry ; 141(11): 1427-9, 1984 Nov.
Article En | MEDLINE | ID: mdl-6437255

The authors present the results of a controlled observation of withdrawal reactions accompanying cessation of desmethyldiazepam (clorazepate) therapy. The two subjects studied had had generalized anxiety disorder for several years; both were free from manifestations of other forms of psychopathology or addictive behavior patterns. Both patients maintained stable patterns of clorazepate use at modest doses for extended periods of time. The findings suggest that the long plasma half-life of clorazepate does not offer unique protection from withdrawal reactions associated with long-term therapy. Manifestations of these withdrawal reactions are indistinguishable from reactions associated with other benzodiazepine compounds.


Anxiety Disorders/chemically induced , Diazepam/analogs & derivatives , Nordazepam/adverse effects , Substance Withdrawal Syndrome/etiology , Acute Disease , Adult , Anxiety Disorders/drug therapy , Anxiety Disorders/psychology , Clinical Trials as Topic , Depression/chemically induced , Diazepam/metabolism , Diazepam/therapeutic use , Feeding and Eating Disorders/chemically induced , Female , Half-Life , Humans , Nausea/chemically induced , Nordazepam/metabolism , Placebos , Psychiatric Status Rating Scales , Sleep Wake Disorders/chemically induced
8.
Psychopharmacology (Berl) ; 70(3): 303-5, 1980.
Article En | MEDLINE | ID: mdl-6777806

Twenty milligram diazepam (DZ) was compared with 20 mg of its main metabolite N-desmethyldiazepam (NDDZ) as single dose, oral premedication in a genuine stressful situation. Fifty patients participated in the randomized, double-blind controlled study. Anxiety and sedation were measured the day before an operation and one hour after premedication, just before the operation. NDDZ was significantly less sedative while the degree of anxiety was rated equal in the two groups. The results may support the hypothesis that a competition between DZ and NDDZ can explain the shift in the effect profile of DZ during long term treatment.


Anxiety/drug therapy , Diazepam/analogs & derivatives , Diazepam/therapeutic use , Hypnotics and Sedatives , Nordazepam/therapeutic use , Adult , Anxiety/etiology , Breast Neoplasms/complications , Diazepam/adverse effects , Double-Blind Method , Drug Evaluation , Emotions/drug effects , Female , Humans , Middle Aged , Nordazepam/adverse effects
...